Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00095 / http://dx.doi.org/10.20960/revcancer.00095

Resumen| PDF

Revisión

Inmunoterapia: un cambio de paradigma en el tratamiento del cáncer de cérvix

Luisa Sánchez Lorenzo, L Montero, Alejandro Gallego, Ángel Vizcay, Antonio González-Martín

Prepublicado: 2024-11-18

Logo Descargas Número de descargas: 3058 Logo Visitas Número de visitas: 101 Citas Citas: 0

Compártelo:

El cáncer de cérvix sigue siendo un importante problema para las mujeres en todo el mundo, a pesar de ser en gran medida prevenible mediante la vacunación y los programas regulares de cribado. En estadios avanzados, la enfermedad se asocia con un pronóstico desfavorable y, durante décadas, las opciones de tratamiento han ofrecido mejoras limitadas, con una tasa de supervivencia global que rara vez superaba los 17 meses. Recientemente, sin embargo, los ensayos clínicos que evaluaron el papel de los inhibidores de puntos de control inmunitarios —tanto como monoterapia como en combinación con quimioterapia— han transformado el panorama terapéutico, logrando resultados sin precedentes. Dado que la inmunoterapia ha redefinido el estándar de atención para el cáncer de cuello uterino metastásico, recurrente y persistente, esta revisión tiene como objetivo proporcionar un análisis exhaustivo de las opciones terapéuticas actuales y señalar áreas clave para futuras investigaciones.

Palabras Clave: Cáncer de cérvix. Inmunoterapia. Terapia sistémica. Terapia dirigida. Quimioterapia.

Descargar PDF

Bibliografía
Artículos Relacionados

Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
DOI: 10.3322/caac.21834

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12.
DOI: 10.1200/JCO.2008.16.4368

Han K, Milosevic M, Fyles A, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013;87:111–9.
DOI: 10.1016/j.ijrobp.2013.05.033

Shrivastava S, Mahantshetty U, Engineer R, et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol 2018;4:506–13.
DOI: 10.1001/jamaoncol.2017.5179

Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–53.
DOI: 10.1056/NEJM199904153401502

Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol 2019;134:49–57.
DOI: 10.1097/AOG.0000000000003311

Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998;42:1015–23.
DOI: 10.1016/S0360-3016(98)00267-3

Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis ofa randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654–63.
DOI: 10.1016/S0140-6736(17)31607-0

Crosbie EJ et al. Human papillomavirus and cervical cancer. Lancet 2013;382:889-99.
DOI: 10.1016/S0140-6736(13)60022-7

Muñoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
DOI: 10.1056/NEJMoa021641

Shah W, Yan X, Jing L, et al. A reversed CD4/ CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 2011; 8: 59–66.
DOI: 10.1038/cmi.2010.56

Komdeur FL, Prins TM, van de Wall S, et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 2017; 6: e1338230.
DOI: 10.1080/2162402X.2017.1338230

Martins PR, Machado CMT, Coxir SA, et al. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. Exp Mol Pathol 2019; 111: 104314.
DOI: 10.1016/j.yexmp.2019.104314

Heeren AM, van Luijk IF, Lakeman J, et al. Neoadjuvant cisplatin and paclitaxel modulate tumor- infiltrating T cells in patients with cervical cancer. Cancer Immunol Immunother 2019; 68: 1759–1767.
DOI: 10.1007/s00262-019-02412-x

Huang RSP, et al. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Mod Pathol. 2021 Jul;34(7):1425-1433.
DOI: 10.1038/s41379-021-00780-3

Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016; 29: 753–763.
DOI: 10.1038/modpathol.2016.64

Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202-206.

Cao J, et al. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Transl Oncol. 2022 Jun;20:101375.
DOI: 10.1016/j.tranon.2022.101375

Cristescu R, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022 Jan;10(1):e003091.
DOI: 10.1136/jitc-2021-003091

Marabelle A, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365
DOI: 10.1016/S1470-2045(20)30445-9

Shao C, et al. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. JAMA Netw Open. 2020 Oct 1;3(10):e2025109.
DOI: 10.1001/jamanetworkopen.2020.25109

Aurora-Garg D, Qiu AAP, et al. Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation Medicine comprehensive genomic platform across cancer types. J Immunoth Cancer 2019; 7: 318.

Ota N, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol. 2022 May;40(5):534-54.
DOI: 10.1007/s11604-021-01230-5

Tewari KS, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022 Feb 10;386(6):544-555.

Frenel JS, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20;35(36):4035-4041
DOI: 10.1200/JCO.2017.74.5471

Chung HC, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478
DOI: 10.1200/JCO.18.01265

Oaknin A, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol. 2024 May;25(5):588-602.
DOI: 10.1016/S1470-2045(24)00088-3

Salani R, et al. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer. 2024 Aug 5;34(8):1140-1148.
DOI: 10.1136/ijgc-2024-005588

Lee JY, Wu L, et al. 744MO AdvanTIG-202: phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) Ann Oncol. 2023;34:S509–S510.
DOI: 10.1016/j.annonc.2023.09.1923

Birrer M, et al. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 25:e242145.
DOI: 10.1001/jamaoncol.2024.2145

Vergote IB, Gonzalez Martin A, Fujiwara K et al. innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Abstract presented at: ESMO Congress 2023, October 20-24, 2023

Vergote I, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023 Dec 20;41(36):5536-5549.
DOI: 10.1200/JCO.23.00720

Oaknin, Ana et al. LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034). Gynecologic Oncology, Volume 166, S24
DOI: 10.1016/S0090-8258(22)01252-5

Gadducci, A., Tana, R., Cosio, S., & Cionini, L. (2010). Treatment options in recurrent cervical cancer (Review) . Oncology Letters, 1, 3-11.
DOI: 10.3892/ol_00000001

Huang H, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial. The Lancet 2017 Oct 7;390(10103):1654–63.37.
DOI: 10.1016/S0140-6736(17)31607-0

Colombo N, et al. KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021 Nov 11;385(20):1856-1867.
DOI: 10.1056/NEJMoa2112435

Monk BJ, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023 Dec 20;41(36):5505-5511.
DOI: 10.1200/JCO.23.00914

Oaknin A, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024 Jan 6;403(10421):31-43.

Lorusso D, et al. Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826. IJGC 2023;33:A1 ESGO 2023 Oral presentation.
DOI: 10.1136/ijgc-2023-ESGO.1

Lou H, et al. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clin Cancer Res. 2024 Apr 15;30(8):1501-1508.
DOI: 10.1158/1078-0432.CCR-23-3162

Mayadev JS, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020 Jan 1;6(1):92-99.
DOI: 10.1001/jamaoncol.2019.3857

Da Silva DM, et al. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 Nov 1;26(21):5621-5630.
DOI: 10.1158/1078-0432.CCR-20-0776

Rodrigues M, et al. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun. 2023;14:3698.
DOI: 10.1038/s41467-023-39383-8

Duska LR, et al. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020 Nov 15;126(22):4948-4956.
DOI: 10.1002/cncr.33136

Monk BJ, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1334-1348.
DOI: 10.1016/S1470-2045(23)00479-5

Lorusso et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2024, Sept.
DOI: 10.1016/S0140-6736(24)01808-7

Garcia-Duran C, et al. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. Int J Gynecol Cancer. 2022 Apr 20:ijgc-2022-003370.
DOI: 10.1136/ijgc-2022-003370

Roussy,G.; Cancer Campus,Grand Paris. Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer; Clinical Trial Registration NCT03612791; clinicaltrials.gov. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT03612791 (accessed on 3 January 2023)

O’Cearbhaill et al. Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024). Gynecol Oncol. 2022;166(suppl 1):S18-S19.
DOI: 10.1016/S0090-8258(22)01242-2

Ray-Coquard I, et al. In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study. J Clin Oncol. 2023;41(16_suppl).
DOI: 10.1200/JCO.2023.41.16_suppl.5501

Nakamura K, et al. Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018. J Clin Oncol. 2023;41(16_suppl) 5514.
DOI: 10.1200/JCO.2023.41.16_suppl.5519

Li K, et al. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(1):76-85.
DOI: 10.1016/S1470-2045(23)00531-4

Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, Li Q. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer. Front Oncol. 2022 Oct 10;12:990877.
DOI: 10.3389/fonc.2022.990877

Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, Sarobe P, Inogés S, Díaz de Cerio AL, Santisteban M. Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers 2024, 16, 981
DOI: 10.3390/cancers16050981

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Líneas de investigación en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Inmunoterapia en hepatocarcinoma

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento perioperatorio del cáncer gástrico

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de estómago recurrente y metastásico en primera línea

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Avances en el tratamiento del cáncer gástrico. Papel de las nuevas terapias dirigidas

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF